The study of genetic traits in intact animals has been facilitated by transgenic and gene-targeting (gene-disruption/ knockout and gene-duplication) experiments in which desired genetic changes are made in the germ-line. Thus, the creation of genetically engineered transgenic mouse and rat models and gene-targeted mouse strains has provided tremendous advancements in biomedical research. The technology to insert, delete, replace, and/or mutate genomic sequences in the living animal models or in specific tissues of interest has provided enhanced opportunities to reproduce or delete the pathogenesis of human diseases and/or to identify their molecular targets. If the gene of interest is quantitive such as blood pressure and cardiovascular function, it requires great efforts to maintain uniform genetic background. The transgenic and gene-targeting technologies provide novel model systems for undertaking the type of investigation through analysis that have either decreased (gene-knockout) or increased (gene-implication) gene copies at the normal chromosomal location controlled by natural regulatory gene sequences. The primary goal of the Transgenic and Gene-Targeted Animal COBRE Core is to provide each investigator an access to our knowledge, resources, and technical support to establish breeding pairs, genotyping, maintain, and generate new colonies of genetically manipulated mouse and rat colonies. For the Phase 111 period, the Transgenic and Gene-Targeted Animal Core facility will be a major resource that will continue providing genetically established mouse and rat models for hypertension and cardiovascular and renal research to the COBRE investigators and others at the Tulane University Health Sciences Center. The core will provide the service, education, and training to our investigators, research fellows, students, and staff to establish, maintain and generate new breeding pairs, genotyping, and characterization of genetically manipulated mice and rat colonies.

Public Health Relevance

The technology to insert, delete,replace, and mutate genomic sequences in the living animals has provided a great opprotunity to reproduce or delete the pathogenesis of human diseases and to identify their molecular targetsand has contributed greatly to our understanding of the pathophysiology of hypertension and associated diseases. The Transgenic and Gene-Targeted Animal COBRE Core will be critical to provide the state-of-art technology to COBRE investigators and to develop novel approaches of research.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
5P30GM103337-03
Application #
8708141
Study Section
Special Emphasis Panel (ZRR1-RI-B)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
3
Fiscal Year
2014
Total Cost
$144,600
Indirect Cost
$48,520
Name
Tulane University
Department
Type
DUNS #
053785812
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Cedillo-Couvert, Esteban A; Ricardo, Ana C; Chen, Jinsong et al. (2018) Self-reported Medication Adherence and CKD Progression. Kidney Int Rep 3:645-651
Liu, Hongbing; Chen, Shaowei; Yao, Xiao et al. (2018) Histone deacetylases 1 and 2 regulate the transcriptional programs of nephron progenitors and renal vesicles. Development 145:
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451
Dobre, Mirela; Gaussoin, Sarah A; Bates, Jeffrey T et al. (2018) Serum Bicarbonate Concentration and Cognitive Function in Hypertensive Adults. Clin J Am Soc Nephrol 13:596-603
Shapiro, Brian P; Ambrosius, Walter T; Blackshear, Joseph L et al. (2018) Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension 71:1064-1074
Rocco, Michael V; Sink, Kaycee M; Lovato, Laura C et al. (2018) Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis 71:352-361
Beddhu, Srinivasan; Greene, Tom; Boucher, Robert et al. (2018) Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol 6:555-563
Anderson, Christopher E; Hamm, L Lee; Batuman, Gem et al. (2018) The association of angiogenic factors and chronic kidney disease. BMC Nephrol 19:117
Lightell Jr, Daniel J; Moss, Stephanie C; Woods, T Cooper (2018) Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus. Atherosclerosis 269:71-78
Dungan, Kathleen; Craven, Timothy E; Soe, Kyaw et al. (2018) Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. Diabetes Obes Metab 20:629-637

Showing the most recent 10 out of 240 publications